Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Baz on Varying Treatment Approaches for Patients With Multiple Myeloma

Rachid Baz, MD
Published: Thursday, May 25, 2017



Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.

Historically, physicians tried to avoid alkylating agents for patients who were eligible for transplant, Baz explains. Now, when considering treatments for elderly patients, the determinant outcome of these patients turns out to be based on fitness or frailty. For patients considered to be frail, a doublet regimen of lenalidomide (Revlimid)/dexamethasone that is dose-adjusted, or a subcutaneous injection of weekly bortezomib (Velcade) and dexamethasone could be choices.

For patients of intermediate fitness, a reasonable treatment would be bortezomib, lenalidomide, and dexamethasone. Emerging, ongoing clinical trials are challenging that data for the future.
 


Rachid Baz, MD, hematologist and medical oncologist, Moffitt Cancer Center, discusses how treatment approaches vary for patients with multiple myeloma.

Historically, physicians tried to avoid alkylating agents for patients who were eligible for transplant, Baz explains. Now, when considering treatments for elderly patients, the determinant outcome of these patients turns out to be based on fitness or frailty. For patients considered to be frail, a doublet regimen of lenalidomide (Revlimid)/dexamethasone that is dose-adjusted, or a subcutaneous injection of weekly bortezomib (Velcade) and dexamethasone could be choices.

For patients of intermediate fitness, a reasonable treatment would be bortezomib, lenalidomide, and dexamethasone. Emerging, ongoing clinical trials are challenging that data for the future.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™ Decision Points in Advanced NSCLC: Assessing Treatment Options Beyond Disease ProgressionNov 30, 20181.0
Community Practice Connections™: Precision Medicine for Community Oncologists: Assessing the Role of Tumor-Testing Technologies in Cancer CareNov 30, 20181.0
Publication Bottom Border
Border Publication
x